Jean Jacques Bienaime bought $204k of IMNM
director at Immunome Inc.. 10,500 shares at an average of $19.45, traded Jun 5, 2026, filed Jun 9, 2026.
Score components
- +15RoleDirector
- +12Trade size$204k at market
- +6Relative to holdingsHoldings up 32%
- +8Price context31% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001221590-26-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | SOpen-market sale Common Stock | -500 | $19.44 | $9,720 | 42,915 | Jun 9, 2026 |
| Jun 5, 2026 | SOpen-market sale Common Stock | -10,000 | $19.41 | $194k | 32,915 | Jun 9, 2026 |
| Jun 5, 2026 | POpen-market purchase Common Stock | +6,000 | $19.48 | $117k | 38,915 | Jun 9, 2026 |
| Jun 5, 2026 | POpen-market purchase Common Stock | +3,500 | $19.46 | $68k | 42,415 | Jun 9, 2026 |
| Jun 5, 2026 | POpen-market purchase Common Stock | +1,000 | $19.27 | $19k | 43,415 | Jun 9, 2026 |
Related signals
Other insiders at Immunome Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Immunome Inc. | Jack Higgins Chief Scientific Officer | $334k 13,200 shares | -17% | |
| 48Moderate | Immunome Inc. | Isaac Barchas director | $2.2M 83,464 shares | -115% | |
| 37Weak | Immunome Inc. | Isaac Barchas director | $940k 36,088 shares | -33% | |
| 33Weak | Immunome Inc. | Kinney Horn CHIEF BUSINESS OFFICER | $2.3M 90,616 shares | -100% | |
| 20Weak | Immunome Inc. | Kinney Horn CHIEF BUSINESS OFFICER | $27k 1,092 shares | -100% | |
| 45Moderate | Immunome Inc. | Isaac Barchas director | $2.4M 100,000 shares | -48% | |
| 40Moderate | Immunome Inc. | Robert Lechleider Chief Medical Officer | $1.2M 55,000 shares | -78% | |
| 45Moderate | Immunome Inc. | Isaac Barchas director | $4.4M 201,050 shares | -49% | |
| 40Moderate | Immunome Inc. | Robert Lechleider Chief Medical Officer | $1.1M 55,000 shares | -78% | |
| 47Moderate | Immunome Inc. | Max Rosett Chief Financial Officer | $1.1M 60,000 shares | -53% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.